A phase 1 dose-escalation trial of intratumoral TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides.
暂无分享,去创建一个
O. Akilov | C. Querfeld | L. Johnson | E. Sievers | M. Irwin | R. Uger | Tina Catalano | Penka S. Petrova | J. Thompson | Matthew H. Taylor